According to a recent LinkedIn post from Engitix Therapeutics, the company has brought in Stewart Bates as VP, Head of Translational Research and Biomarkers. The post notes that Bates has nearly three decades of drug development experience and has led biomarker platforms and clinical biomarker programs from Phase 1 through Phase 3.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post highlights Bates’s prior leadership roles at Johnson & Johnson, where he led Discovery and Translational Sciences in Interventional Oncology, and his more than 22-year tenure at GSK, most recently as Senior Director in the Clinical Biomarker Group. This background suggests Engitix is seeking to strengthen its translational and biomarker capabilities as it advances its pipeline.
As shared in the post, Bates will oversee biomarker strategy across Engitix’s oncology and anti-fibrosis programs and contribute scientific insight to the design and execution of biomarker work as the company’s ECM platform moves toward clinical development. For investors, this senior hiring move may indicate an effort to de-risk future trials, improve patient stratification, and position the company more competitively in oncology and fibrosis drug development.